http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EC-SP024364-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7f82940e47ba7a1188f8e2ffca55e0f
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
filingDate 2002-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afabe4132e4fc910f8841120eca5000d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e5cd896d02f0a225e704543422bea06d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4614955bb8a480b463637fda3a96d66b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6421bffda7ffbc13e5b8958d0aa2586e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18d19bbca22f41ebcde62451b2573d8e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c563ae7386f419bd6ede49d92d21ef4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93635decfd4e628ef854d34a0c08a8a9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6cabc765bf3c49b959b63d0a7d996af7
publicationDate 2003-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EC-SP024364-A
titleOfInvention ADENOSINE A2A RECEIVING ANTAGONISTS
abstract Compounds having the structural formula I or one of them pharmaceutically acceptable, in which R is optionally substituted phenyl, cycloalkenyl or heteroaryl X is alkylene or C (O) CH2 Y is N (R2) CH2 CH2 (R3) -, - OCH2 CH2 N (R2) -, -0-, -S-, -ch2s-, - (ch2 (2-NH-, or optionally substituted, - (graph) - r m and n are 2-3, and- Q is nitrogen or optionally substituted carbon; Z is optionally substituted phenyl, phenyl, phenylalkyl or heteroaryl, diphenylmethyl (graph) R6_ C (0 = -, R6_SO2-, R6-0C (o) -, R7- N (R8) -C (0) -, R7- N (R8) -C (S) -, phenyl- CH (OH) -, or phenyl- C - (= NOR2) -; 0 when Q is CH, phenylamino or pyridylamino; 0 Z and Y together are substituted piperidinyl or substituted phenyl; and R2, R3, R6, R7, and R8 are as defined herein, and their use for the treatment of Parkinson's disease, alone or in combination with other agents to treat the disease of Parkinson, and the pharmaceutical compositions comprising them; and also described n a process for preparing intermediate useful for preparing compounds of formula I.
priorityDate 2000-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394811
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419579030
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419554679
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID947
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458395511
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID222
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394830
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID432787922
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID447916
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419556970
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID448378

Total number of triples: 42.